Evidence map›Paper›PMID 42910049›Full record

ArticleClinical and translational radiation oncology2027

Study protocol for the TROG 21.08 VITaL trial: a randomized controlled trial investigating ventilation imaging to improve the quality of life for patients with lung cancer treated with radiation therapy.

Shalini K Vino D, Val Gebski, Sashendra Senthi, Cynleen Kai, Dasantha Jayamanne, David Palma, Nicholas Hardcastle, Hilary L Byrne, Douglas A Hoover, John Kipritidis and 16 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06127654 (VITaL), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06127654 phase3recruitingnot on this map

VITaL: A Randomised Controlled Trial Investigating Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy

TypeinterventionalSponsorUniversity of SydneyRan2026 to 2028Enrolled165ConditionsLung CancerArmsHealthy lung sparing treatment plan
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Shalini K Vino DCancer Therapy Centre, Liverpool Hospital, South Western Sydney Local Health District, NSW, Australia.
Val GebskiSydney Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Sashendra SenthiAlfred Health Radiation Oncology, Melbourne, VIC, Australia.
Cynleen KaiAustin Health, Melbourne, VIC, Australia.
Dasantha JayamanneNorthern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, Australia.
David PalmaVerspeeten Family Cancer Centre, London Health Sciences Centre, London, Ontario, Canada.
Nicholas HardcastleDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Hilary L ByrneGenesis Care, Sydney, NSW, Australia.
Douglas A HooverVerspeeten Family Cancer Centre, London Health Sciences Centre, London, Ontario, Canada.
John KipritidisNorthern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, Australia.
Anthony EspinozaCancer Therapy Centre, Liverpool Hospital, South Western Sydney Local Health District, NSW, Australia.
Benjamin ZwanCentral Coast Cancer Centre, Gosford Hospital, Gosford, NSW, Australia.
Guneet KaurGenesis Care, Sydney, NSW, Australia.
Amit SawantDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Bilal A TahirPOLARIS, Section of Medical Imaging and Technologies, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom.
Rebecca Mercieca-BebberSydney Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Karan K ShahSydney Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Andrew BowenThoracic Oncology Group of Australasia, Thornbury VIC, Australia.
Miriam CavanaghFaculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia.
Lee HuntCancer Voices NSW, Milsons Point, NSW, Australia.
Surein ArulanandaDepartment of Medical Oncology, Monash Health, Melbourne, VIC, Australia.
Helen BallImage X Institute, Sydney School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Nina Eikelis4DMedical, Melbourne, VIC, Australia.
Alisha MooreTrans-Tasman Radiation Oncology Group, Waratah, NSW, Australia.
Shona SilvesterImage X Institute, Sydney School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Paul KeallImage X Institute, Sydney School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Radiation therapy (RT) is indicated for 77% of patients with lung cancer. Over 20% of patients are affected by radiation-induced lung injury. Computed tomography ventilation imaging (CTVI) estimates high and low functioning lung regions. During RT planning, CTVI can guide preferential avoidance of higher ventilated regions by redirecting dose to less well ventilated regions, sparing healthy lung tissue. The double-masked randomized Trans-Tasman Radiation Oncology Group (TROG) 21.08 VITaL trial will investigate if sparing healthy lung can improve the quality of life (QoL) for patients with stage 3 non-small cell lung cancer (NSCLC) treated with RT. Methods: 165 patients will be recruited to test the hypothesis that patients receiving healthy lung-sparing RT have better QoL than patients receiving standard RT. CTVI will be generated from exhale and inhale breath-hold CT scan pairs. A healthy lung-sparing plan and a standard treatment plan will be created for each patient and randomly assigned in a 1:1 ratio for the patient's treatment. QoL will be assessed with the Functional Assessment of Cancer Therapy-Lung questionnaire before and after treatment. Secondary hypotheses include that patients in the healthy lung-sparing arm will have fewer treatment side effects, better lung function, be more likely to receive and complete adjuvant immunotherapy, and healthy lung-sparing treatment will be cost-effective. Patient follow-up will continue for three years. Discussion: This prospective randomized trial will determine whether the incorporation of healthy lung-sparing RT based on CTVI improves QoL, reduces pulmonary toxicity, and increases eligibility to receive curative immunotherapy for patients with stage 3 NSCLC. Trial Registration: ClinicalTrials.gov (NCT06127654).

Indexed as

CT ventilation imagingFunctional imagingHealthy lung-sparingLung cancerPneumonitisQuality of life

Identifiers

PMID42910049
PMCPMC13684938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.